Adipokines and vascular risk in type 2 diabetes mellitus

Angiology

Volumn 62, Issue 8, 2011, Pages 601-604

  Katsiki, Niki ^a   Yovos, John G ^a   Gotzamani Psarrakou, Anna ^a   Karamitsos, Dimitrios T ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PIOGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CORONARY STENT; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE;

ADIPONECTIN; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; E-SELECTIN; HUMANS; MALE; OBESITY;

EID: 80054758169     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319711409201     Document Type: Article

References (68)

1. El-Mesallamy HO, Hamdy NM, Salman TM, Mahmoud S. Adiponectin and E-selectin concentrations in relation to inflammation in obese type 2 diabetic patients with coronary heart disease(s). Angiology. 2011 ;:
2. Katsiki N, Mikhailidis DP, Gotzamani-Psarrakou A, Yovos JG, Karamitsos D. Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. Expert Opin Ther Targets. 2011 ; 15 (4). 401-420
3. Kashyap SR, Roman LJ, Mandarino L, DeFronzo R, Bajaj M. Hypoadiponectinemia is closely associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. Metab Syndr Relat Disord. 2010 ; 8 (5). 459-463
4. Taniguchi A, Fukushima M, Ohya M, et al. Interleukin 6, adiponectin, leptin, and insulin resistance in nonobese Japanese type 2 diabetic patients. Metabolism. 2006 ; 55 (2). 258-262 (Pubitemid 43098996)
5. Kowalska I, Straczkowski M, Nikoajuk A, et al. Plasma adiponectin and E-selectin concentrations in patients with coronary heart disease and newly diagnosed disturbances of glucose metabolism. Adv Med Sci. 2006 ; 51: 94-97
6. Brochu-Gaudreau K, Rehfeldt C, Blouin R, Bordignon V, Murphy BD, Palin MF. Adiponectin action from head to toe. Endocrine. 2010 ; 37 (1). 11-32
7. Goldstein BJ, Scalia RG, Ma XL. Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med. 2009 ; 6 (1). 27-35
8. Cui J, Panse S, Falkner B. The role of adiponectin in metabolic and vascular disease: a review. Clin Nephrol. 2011 ; 75 (1). 26-33
9. Kawano J, Arora R. The role of adiponectin in obesity, diabetes, and cardiovascular disease. J Cardiometab Syndr. 2009 ; 4 (1). 44-49
10. Shibata R, Ouchi N, Murohara T. Adiponectin and cardiovascular disease. Circ J. 2009 ; 73 (4). 608-614
11. Kiris I, Tekin I, Yesildag A, et al. Inverse relationship between adiponectin levels and subclinical carotid atherosclerosis in patients undergoing coronary artery bypass grafting. Int Heart J. 2006 ; 47 (6). 855-866
12. Wolk R, Berger P, Lennon RJ, Brilakis ES, Davison DE, Somers VK. Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J. 2007 ; 28 (3). 292-298
13. Dekker JM, Funahashi T, Nijpels G, et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab. 2008 ; 93 (4). 1489-1496 (Pubitemid 351519753)
14. Yilmaz MI, Saglam M, Qureshi AR, et al. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant. 2008 ; 23 (5). 1621-1627 (Pubitemid 351767738)
15. Kato K, Osawa H, Ochi M, et al. Serum total and high molecular weight adiponectin levels are correlated with the severity of diabetic retinopathy and nephropathy. Clin Endocrinol (Oxf). 2008 ; 68 (3). 442-449 (Pubitemid 351257865)
16. Zietz B, Buechler C, Kobuch K, Neumeier M, Schölmerich J, Schäffler A. Serum levels of adiponectin are associated with diabetic retinopathy and with adiponectin gene mutations in Caucasian patients with diabetes mellitus type 2. Exp Clin Endocrinol Diabetes. 2008 ; 116 (9). 532-536
17. Tuttolomondo A, La Placa S, Di Raimondo D, et al. Adiponectin, resistin and IL-6 plasma levels in subjects with diabetic foot and possible correlations with clinical variables and cardiovascular co-morbidity. Cardiovasc Diabetol. 2010 ; 9: 50
18. Hajer GR, van der Graaf Y, Olijhoek JK, Edlinger M, Visseren FL. Low plasma levels of adiponectin are associated with low risk for future cardiovascular events in patients with clinical evident vascular disease. Am Heart J. 2007 ; 154 (4). 750.e1 - e7
19. Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S. Significance of chemokines and activated platelets in patients with diabetes. Clin Exp Immunol. 2000 ; 121 (3). 437-443
20. Haubner F, Lehle K, Münzel D, Schmid C, Birnbaum DE, Preuner JG. Hyperglycemia increases the levels of vascular cellular adhesion molecule-1 and monocyte-chemoattractant-protein-1 in the diabetic endothelial cell. Biochem Biophys Res Commun. 2007 ; 360 (3). 560-565 (Pubitemid 47048136)
21. Feng L, Matsumoto C, Schwartz A, Schmidt AM, Stern DM, Pile-Spellman J. Chronic vascular inflammation in patients with type 2 diabetes: endothelial biopsy and RT-PCR analysis. Diabetes Care. 2005 ; 28 (2). 379-384 (Pubitemid 40170943)
22. Davì G, Tuttolomondo A, Santilli F, et al. CD40 ligand and MCP-1 as predictors of cardiovascular events in diabetic patients with stroke. J Atheroscler Thromb. 2009 ; 16 (6). 707-713
23. Piemonti L, Calori G, Lattuada G, et al. Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals. Diabetes Care. 2009 ; 32 (11). 2105-2110
24. Yuasa S, Maruyama T, Yamamoto Y, et al. MCP-1 gene A-2518G polymorphism and carotid artery atherosclerosis in patients with type 2 diabetes. Diabetes Res Clin Pract. 2009 ; 86 (3). 193-198
25. Oh IK, Kim SW, Oh J, Lee TS, Huh K. Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy. Curr Eye Res. 2010 ; 35 (12). 1116-1127
26. Giunti S, Barutta F, Perin PC, Gruden G. Targeting the MCP-1/CCR2 System in diabetic kidney disease. Curr Vasc Pharmacol. 2010 ; 8 (6). 849-860
27. Reilly MP, Iqbal N, Schutta M, et al. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab. 2004 ; 89 (8). 3872-3878 (Pubitemid 39071487)
28. Kim SK, Kim HJ, Ahn CW, et al. Hyperleptinemia as a robust risk factor of coronary artery disease and metabolic syndrome in type 2 diabetic patients. Endocr J. 2008 ; 55 (6). 1085-1092
29. Taniguchi A, Fukushima M, Nakai Y, et al. Factors responsible for the evolution of insulin resistance in Japanese type 2 diabetic patients: association with atherosclerosis. Diabetes Res Clin Pract. 2007 ; 77 (suppl 1). S213 - S219
30. Nishio K, Sakurai M, Kusuyama T, et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care. 2006 ; 29 (1). 101-106 (Pubitemid 44033439)
31. Ruige JB, Mertens I, Considine RV, Paelinck BP, Van Gaal LF. Opposite effects of insulin-like molecules and leptin in coronary heart disease of type 2 diabetes Preliminary data. Int J Cardiol. 2006 ; 111 (1). 19-25 (Pubitemid 44107533)
32. Bountouris I, Paraskevas KI, Koutouzis M, et al. Serum leptin levels in patients undergoing carotid endarterectomy: a pilot study. Angiology. 2009 ; 60 (6). 698-704
33. Abdella NA, Mojiminiyi OA, Moussa MA, et al. Plasma leptin concentration in patients with Type 2 diabetes: relationship to cardiovascular disease risk factors and insulin resistance. Diabet Med. 2005 ; 22 (3). 278-285 (Pubitemid 40313854)
34. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care. 2004 ; 27 (10). 2450-2457 (Pubitemid 39281400)
35. Takata Y, Osawa H, Kurata M, et al. Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension. 2008 ; 51 (2). 534-539 (Pubitemid 351156444)
36. On YK, Park HK, Hyon MS, Jeon ES. Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients. Circ J. 2007 ; 71 (6). 868-873
37. Osawa H, Ochi M, Tabara Y, et al. Serum resistin is positively correlated with the accumulation of metabolic syndrome factors in type 2 diabetes. Clin Endocrinol (Oxf). 2008 ; 69 (1). 74-80 (Pubitemid 351847266)
38. Osawa H, Ochi M, Kato K, et al. Serum resistin is associated with the severity of microangiopathies in type 2 diabetes. Biochem Biophys Res Commun. 2007 ; 355 (2). 342-346
39. Martens FM, Rabelink TJ, op't Roodt J, de Koning EJ, Visseren FL. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur Heart J. 2006 ; 27 (13). 1605-1609 (Pubitemid 43954922)
40. Akalin A, Alatas O, Colak O. Relation of plasma homocysteine levels to atherosclerotic vascular disease and inflammation markers in type 2 diabetic patients. Eur J Endocrinol. 2008 ; 158 (1). 47-52 (Pubitemid 351211039)
41. Pu LJ, Lu L, Shen WF, et al. Increased serum glycated albumin level is associated with the presence and severity of coronary artery disease in type 2 diabetic patients. Circ J. 2007 ; 71 (7). 1067-1073 (Pubitemid 46998021)
42. Hirota T, Suzuki E, Ito I, et al. Coronary artery calcification, arterial stiffness and renal insufficiency associate with serum levels of tumor necrosis factor-alpha in Japanese type 2 diabetic patients. Diabetes Res Clin Pract. 2008 ; 82 (1). 58-65
43. Lu L, Pu LJ, Xu XW, et al. Association of serum levels of glycated albumin, C-reactive protein and tumor necrosis factor-alpha with the severity of coronary artery disease and renal impairment in patients with type 2 diabetes mellitus. Clin Biochem. 2007 ; 40 (11). 810-816 (Pubitemid 46961968)
44. Kaul K, Hodgkinson A, Tarr JM, Kohner EM, Chibber R. Is inflammation a common retinal-renal-nerve pathogenic link in diabetes?. Curr Diabetes Rev. 2010 ; 6 (5). 294-303
45. Lee JH, Lee W, Kwon OH, et al. Cytokine profile of peripheral blood in type 2 diabetes mellitus patients with diabetic retinopathy. Ann Clin Lab Sci. 2008 ; 38 (4). 361-367
46. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol. 2008 ; 30 (2). 65-84
47. Navarro-González JF, Jarque A, Muros M, Mora C, García J. Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy. Cytokine Growth Factor Rev. 2009 ; 20 (2). 165-173
48. Drel VR, Lupachyk S, Shevalye H, et al. New therapeutic and biomarker discovery for peripheral diabetic neuropathy: PARP inhibitor, nitrotyrosine, and tumor necrosis factor-{alpha}. Endocrinology. 2010 ; 151 (6). 2547-2555
49. Krayenbuehl PA, Wiesli P, Schmid M, et al. TNF-alpha-308G>A polymorphism modulates cytokine serum concentrations and macrovascular complications in diabetic patients on aspirin. Exp Clin Endocrinol Diabetes. 2007 ; 115 (5). 322-326 (Pubitemid 46877866)
50. Vendrell J, Fernandez-Real JM, Gutierrez C, et al. A polymorphism in the promoter of the tumor necrosis factor-alpha gene (-308) is associated with coronary heart disease in type 2 diabetic patients. Atherosclerosis. 2003 ; 167 (2). 257-264 (Pubitemid 36773525)
51. Souza JR, Oliveira RT, Blotta MH, Coelho OR. Serum levels of interleukin-6 (Il-6), interleukin-18 (Il-18) and C-reactive protein (CRP) in patients with type-2 diabetes and acute coronary syndrome without ST-segment elevation. Arq Bras Cardiol. 2008 ; 90 (2). 86-90
52. Johansen OE, Birkeland KI, Orvik E, et al. Inflammation and coronary angiography in asymptomatic type 2 diabetic subjects. Scand J Clin Lab Invest. 2007 ; 67 (3). 306-316 (Pubitemid 46643379)
53. Mavridis G, Souliou E, Diza E, et al. Inflammatory cytokines in insulin-treated patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2008 ; 18 (7). 471-476
54. James SK, Lindahl B, Timmer JR, et al. Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy). Am J Cardiol. 2006 ; 97 (2). 167-172 (Pubitemid 43139229)
55. Shinohara T, Takahashi N, Yufu K, et al. Role of interleukin-6 levels in cardiovascular autonomic dysfunction in type 2 diabetic patients. Eur J Nucl Med Mol Imaging. 2008 ; 35 (9). 1616-1623
56. Libra M, Signorelli SS, Bevelacqua Y, et al. Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. J Clin Pathol. 2006 ; 59 (2). 211-215 (Pubitemid 43235590)
57. Xu L, Jiang CQ, Lam TH, Bao B, Cheng KK, Thomas GN. Plasminogen activator inhibitor-1 and HbA1c defined prediabetes: the Guangzhou Biobank Cohort Study-CVD. Clin Endocrinol (Oxf). 2011 ; 74 (4). 528-531
58. Alizadeh Dehnavi R, Beishuizen ED, van de Ree MA, et al. The impact of metabolic syndrome and CRP on vascular phenotype in type 2 diabetes mellitus. Eur J Intern Med. 2008 ; 19 (2). 115-121 (Pubitemid 351179290)
59. Brazionis L, Yau J, Rowley K, et al. Plasminogen activator inhibitor-1 (PAI-1) activity and retinal vascular calibre in type 2 diabetes. Diabetes Res Clin Pract. 2010 ; 87 (2). 192-199
60. Madan R, Gupt B, Saluja S, Kansra UC, Tripathi BK, Guliani BP. Coagulation profile in diabetes and its association with diabetic microvascular complications. J Assoc Physicians India. 2010 ; 58: 481-484
61. Erem C, Hacihasanoaylu A, Celik S, et al. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications. Med Princ Pract. 2005 ; 14 (1). 22-30
62. Szelag B, Wroblewski M, Castenfors J, et al. Obesity, microalbuminuria, hyperinsulinemia, and increased plasminogen activator inhibitor 1 activity associated with parasympathetic neuropathy in type 2 diabetes. Diabetes Care. 1999 ; 22 (11). 1907-1908 (Pubitemid 29521884)
63. Boyle PJ. Diabetes mellitus and macrovascular disease: mechanisms and mediators. Am J Med. 2007 ; 120 (9 suppl 2). S12 - S17
64. Dunn EJ, Grant PJ. Type 2 diabetes: an atherothrombotic syndrome. Curr Mol Med. 2005 ; 5 (3). 323-332 (Pubitemid 40663137)
65. Athyros VG, Tziomalos K, Karagiannis A, Anagnostis P, Mikhailidis DP. Should adipokines be considered in the choice of the treatment of obesity-related health problems?. Curr Drug Targets. 2010 ; 11 (1). 122-135
66. Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother. 2008 ; 9 (7). 1087-1108 (Pubitemid 351721748)
67. Paraskevas KI, Liapis CD, Mikhailidis DP. Leptin: a promising therapeutic target with pleiotropic action besides body weight regulation. Curr Drug Targets. 2006 ; 7 (6). 761-771 (Pubitemid 43827272)
68. Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS. A review of the metabolic effects of sibutramine. Curr Med Res Opin. 2005 ; 21 (3). 457-468